About Nutrinia

Nutrinia's Market Focus is Neonatal GI Rehabilitation and Maturation

Nutrinia is a neonatology company developing pharmaceuticals to treat rare conditions of the gastrointestinal tract. Our current products in development are oral formulations of insulin shown to enhance adaptation and rehabilitation of the gut in infants. We at Nutrinia live by the belief that science is best used to make life better for people, especially the most vulnerable populations. 

Management Team

Our qualified team members
Jill Thompson Quigley, Esq.
Interim CEO
Ms. Quigley is the interim Chief Executive Officer, General Counsel and Chief Administrative Officer of Nutrinia. Previously, Ms. Quigley served as legal counsel at several biotechnology companies, including as Senior Counsel at Shire plc, NPS Pharmaceuticals, Inc. where she served in several capacities including Interim General Counsel and a member of the Board of Directors for several foreign subsidiaries and was a key member of the NPS transaction team in it’s $5.2B acquisition by Shire, and Pharmasset, Inc., where she led the company’s regulatory compliance program and was integral in the negotiations that lead to the record-setting $11B acquisition by Gilead Sciences. Ms. Quigley began her career as an associate with the law firm of Dechert LLP, where she advised life science companies on a broad range of business and legal matters. She received an B.A. from American University and a J.D. with high honors from Rutgers School of Law.
Nader N. Youssef, MD
Dr. Youssef brings 17 years of clinical, academic, and industry experience. He recently led the Global Program Team at NPS Pharmaceuticals for Gattex/Revestive for short bowel syndrome, where his team secured marketing authorization in the US, Canada, and EU. Before NPS, he worked on GI motility programs as Director of Research at AstraZeneca. Dr. Youssef graduated from Ross University School of Medicine, completed pediatric residency at Robert Wood Johnson Hospital, fellowship in Pediatric Gastroenterology/Hepatology and Nutrition at Children’s Hospital of Pittsburgh specializing in Neurogastroenterology and Intestinal Failure. He is a Fellow of the American Academy of Pediatrics and American College of Gastroenterology. He received a BS in finance from Stern School of Business at New York University and Executive MBA from Katz School of Business at University of Pittsburgh.
Dr. Jon Beauchamp, MBBS
SVP European Operations
Dr Jon Beauchamp trained in medicine and practiced in the UK and Australia before joining the biotech industry in 2005. Prior to joining Nutrinia, Jon spent 9 years at Alexion where he brought therapy expertise as VP Global Medical Affairs Lead Nephrology, European leadership as VP EMEA Medical Affairs as well as commercial leading sales, marketing and diagnostics as Business Unit Lead for Soliris. Jon studied medicine in London.
Tom Biancardi
SVP, Finance & Business Planning
Tom Biancardi has over 20 years of financial leadership experience in the biotech/pharmaceutical industry. Prior to joining Nutrinia, Tom worked with Ophthotech Corporation in senior leadership roles in both finance and commercial planning. As the Vice President of Finance and Operations, he played a key role in raising over $800MM including several private venture raises, an IPO, and a landmark ex-US licensing deal. Prior to Ophthotech, Tom worked with Eyetech Pharmaceuticals as the Senior Director of Finance and Operations where he acted as the Chief Financial Officer of the Eyetech Business Unit as well as the strategic planning/business analytics lead. Tom also worked at Pfizer for 5 years in increasing roles of responsibility within both corporate and commercial finance. Tom holds an M.B.A. from New York University, and Bachelor of Science degrees in both Mechanical Engineering and Economics from Rutgers University.
Naim Shehadeh, MD
Dr. Shehadeh is a leading researcher in the field of juvenile diabetes. Driven by the vision of making a milk replacement formula as healthy as mother’s milk, Dr. Shehadeh progressed from his clinical studies of insulin concentration in human milk to a practical application for delivery of bioactive proteins in commercial infant formula. He is Director of Pediatrics A and the Pediatric Diabetes Unit at Meyer Children’s Hospital of Haifa at Rambam Medical Center. Prof. Shehadeh has received a number of research and innovation awards, including the Hershel Rich Technion Innovation Award and the Raymond and Miriam Klein Technion Research Award.
Raanan Shamir, MD
Medical Advisor
Raanan Shamir is currently the chairman of the Institute of Gastroenterology, Nutrition, and Liver Diseases at Schneider Children’s Medical Center of Israel, and is a professor of Pediatrics at the Sackler Faculty of Medicine at Tel Aviv University, Israel. Prof. Shamir received his MD degree from Hebrew University in Jerusalem, Israel, and trained in Pediatrics at the Beilinson Medical Center, in Petach-Tiqva, Israel.

Board of Directors

Stephen Squinto, Ph.D.
Executive Chairman
Stephen is a Venture Partner with OrbiMed who brings over 25 years of biotechnology industry experience. Dr. Squinto was a co-founder of Alexion Pharmaceuticals, Inc. and recently served as its Executive Vice President and Chief Global Operations Officer. Prior to 2013, he was Alexion’s Global Head of Research and Development. He is a recipient of numerous honors and awards from academic and professional organizations for his scientific work. Dr. Squinto received his B.A. in Chemistry and Ph.D. in Biochemistry and Biophysics from Loyola University of Chicago.
Anat Naschitz
Board Member
Anat Naschitz, Managing Director at OrbiMed, has over 19 years of international healthcare operational and investment experience. OrbiMed Advisors LLC is a leading healthcare investment firm, with approximately $12 billion in assets under management. OrbiMed invests globally out of five offices – New York, Tel Aviv, San Francisco, Shanghai and Mumbai – in private and public companies across stages, through a series of funds. OrbiMed Israel has $222 million in committed capital.
Gary Jacobs
Board Member
Mr. Gary Jacobs is the Founder and Managing Director of Jacobs Investment Company LLC (JIC).  JIC invests in many technological companies both in the US and Israel. Mr. Jacobs serves on numerous boards, including NGT3 technological incubator Nazareth. In the community, Mr. Jacobs is the Past President of the United Jewish Federation of San Diego County. In addition Mr. Jacobs serves as Chairman of the Board of Trustees of the Gary and Jerri-Ann Jacobs High Tech High, a charter high school. Gary and Jerri-Ann Jacobs are the founders of JITLI -International Teen Leadership Institute.
Aaron Davidson
Board Member
Mr. Davidson is Co-head and Managing Director of H.I.G. BioHealth Partners where he focuses on investment opportunities in the life sciences sector. He began his career with Eli Lilly and Company, where he spent a decade in various management roles in the United States and Canada including general management, business development, strategic planning, market research and financial planning. Mr. Davidson currently serves on the boards of HyperBranch Medical Technology, Intact Vascular, Nutrinia Limited and On Target Laboratories. He represented H.I.G. as a board member in several successful companies including: Alder Biopharmaceuticals (public), Forsight Vision5 (acquired), Gemin X Pharmaceuticals (acquired), Novadaq Technologies (public/acquired), and Salmedix (acquired). Mr. Davidson earned his MBA from Harvard Business School and a bachelor’s degree from McGill University.
Eran Nadav, Ph.D.
Board Member
Dr. Nadav serves as Partner and Managing Director at TPG Biotech, the life science venture investment arm of the global private investment firm TPG. He joined TPG in 2007, to invest in pharmaceuticals and biotechnology across various geographies and stages of development. Prior to TPG, he served as Business Development Director at Eisai, where he evaluated and negotiated licensing and acquisition deals. Prior to that, Dr. Nadav worked for the Israeli office of JJDC, the venture capital subsidiary of Johnson & Johnson. Previously, Dr. Nadav worked for Neurim Pharmaceuticals Ltd. supporting the clinical development of Circadin®. He holds a Ph.D. in Biochemistry, M.Sc. magna cum laude, B.Sc. magna cum laude, and MBA from Tel Aviv University. Dr. Nadav is currently Chairman of the Board of Trevi Therapeutics, and board member at Collegium Pharmaceutical (Nasdaq: COLL), ShangPharma (a China based CRO), and NovaSom. He was the lead investor and Chairman of the Board of Ultragenyx Pharmaceutical (Nasdaq: RARE). His other past investments and board roles include JCR Pharmaceuticals (a Japanese biopharma company, TSE: 4552), MacroGenics (Nasdaq: MGNX), and Mey Eden.
Tomer Kariv
Board Member
Tomer is the co-founder and Chief Executive Officer of Pontifax. He serves as an active board member of many of the funds’ portfolio companies, assuming a special responsibility for strategic planning. Among other positions, Tomer serves as the Chairman of Check-Cap and is a board member at Macrocure and V-Wave. During the 10 years prior to establishing Pontifax, he held senior management positions at top Israeli financial institutions, playing a key role in investing in, nurturing and managing technology driven startups. Tomer holds a B.A. in Economics from Harvard University and a J.D. from Harvard Law School.
Wei Li, Ph.D.
Board Member
Dr. Li is Managing Director of WuXi Healthcare Ventures II, with over 20 years of experience as a successful executive and entrepreneur in the biotech industry. Prior to joining WuXi Healthcare Ventures, Dr. Li focused his effort on healthcare and life science investment opportunities at Fidelity Biosciences, Fidelity Growth Partner Asia, and Baird Venture Partners. He also led drug discovery projects and technology licensing due diligence at Vertex Pharmaceuticals. During his scientific career, Wei authored numerous scientific publications in journals such as Science, Proceedings of the National Academy of Sciences, and the Journal of Biological Chemistry. Dr. Li received a B.S., with distinction, in Chemical Physics from University of Science and Technology of China, a Ph.D. in Biochemistry and Mammalian Genetics from Harvard University, and an MBA from the Kellogg School of Management at Northwestern University, where he was elected Beta Gamma Sigma, with a concentration in Finance, Accounting and Marketing.


Jorge Ramirez
Jorge Ramirez is a Vice President at H.I.G. BioHealth Partners, and previously was with ProQuest Investments. During his eight years at ProQuest, he was an observer or board member at several successful companies including: Eagle Pharmaceuticals (NASDAQ: EGRX), Mevion Medical Systems, Revision Optics, Orthocon (acquired by AbyRx), and MethylGene (now Mirati Pharmaceutics: NASDAQ: MRTX). He was also the General Manager of Neurology Products at Cyberkinetics Neurotechnology Systems, where he led the regulatory and clinical development teams for an epilepsy monitoring device and had P&L responsibility for Cyberkinetics’ research products. Previously, Mr. Ramirez was a management consultant at Monitor Company. Mr. Ramirez earned degrees in Neuroscience and Spanish literature from Amherst College, where he graduated magna cum laude. He earned an MBA from Harvard Business School, where he was a Pfizer Scholar and Social Enterprise Fellow.
Nizar Mishael
Nizar Mishael is the founder and Managing Director of NGT3VC. Nizar has over 11 years of healthcare financial and investment experience. NGT3VC is an early-stage venture capital fund, focused on medical device and life science technologies and holder of a government franchise to operate a technology incubator. Nizar manages the finances of NGT3 and its portfolio companies with strong leadership, experience and understanding of both financial and business aspects and takes an active role with follow-on funding and handling complex investment transactions. Nizar is a certified CPA and holds an MBA from Tel Aviv University’s Recanati program.

Our Investors

We Have the Best Investors and Partners
Orbimed logo
Pontifax Logo Small
Wuxi Logo 1
HIG Capital
Maabarot Logo